Start-up ... Clovis Oncology ... Raises Astounding $145M Venture Capital Round

[CC-Conrad Clyburn-MedForeSight]

Colleagues,

As reported in Iguana Bio ... Start-up company Clovis Oncology has raised an astonishing $145M from the big players in Venture Capital ... Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures and ProQuest Investments.

I assume the magic is in the business model? The Clovis business model will be based on “acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.” The company didn’t make an announcement as to whether it already had acquired any products, but we assume they must have something in the works to secure such a massive amount of cash.

Building on its core competencies in clinical development, regulatory affairs and commercialization of innovative anti-cancer agents, Clovis intends to license or acquire rights to oncology compounds in all stages of clinical development.

Clovis will be focused on partnering with discovery-based companies and taking responsibility for developing and commercializing innovative products that may ultimately provide significant benefit to cancer patients. The Company is headquartered in Boulder, Colorado, and is establishing additional offices in San Francisco and London.

The company’s founders are all former execs of Pharmion (acquired by Celgene in 2008 for $2.9B) and will be taking their same management roles at Clovis.

Read on at: http://www.iguanabio.com/start-up-clovis-oncology-raises-a-massive-...

Tips? Comments? Contact Iguana Bio at: [e-mail]

ENJOY!

CC